Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.
Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey highlighted the cost savings across stakeholder groups caused by their collaborative oncology therapeutics home infusion pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health; she also predicted what cost savings would occur in the future as their program continues. Jan went into more depth about this and other aspects of the program during the AMCP Nexus session "Implementation of a Novel Oncology Home Infusion Model" on October 18.
At Horizon Blue Cross Blue Shield of New Jersey, Jan is the vice president and chief pharmacy officer. She is also professor emerita at Rutgers University's Ernest Mario School of Pharmacy.
This transcript has been lightly edited for clarity.
Transcript
Could you discuss the total savings accomplished through this program?
When we started the program, the biggest focus was not cost savings; the focus was improving quality, improving accessibility, and making sure the patient gets full chemotherapy in their home. Since we were doing it for other therapies, why could we not do this with oncology?
Interestingly, we saw close to $1 million in savings in the initial 50-patient analysis. We have not incorporated in this the savings that the hospital saw by having additional chairs filled for additional infusions. It is still in the works, but you can imagine that home infusions reduced the hospital-related infusion cost, so that was a significant amount.
Robert Wood Johnson Cancer Institute has now made this business as usual. We ended this pilot in December, and, from January this year, it is business as usual; when the members walk in, they offer that as an option if they want to be infused at home.
The cost savings will come, not only by the backfill to the hospital; from the hospital, it's the cost saved through the added number of patients by backfilling the chairs. For a payer, it is the infusion costs at home. We also work with the benefit design to say member cost sharing should not be high when they're getting an at home infusion.
The bigger cost savings would be having the chemotherapy completed in their given time versus dropping because they don't want to go to the hospital, and that total health outcome due to that chemotherapy is something that will have to be measured in the long run, because if you would not complete your course, there are other implications of disease progression or getting more add-on therapies because now the patient is not controlled. Those aspects we have not even looked at at this point, but that's the premises of why home oncology is critical.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More